Introduction
Naturally-occurring regulatory T (nT REG ) cells are a central component of peripheral tolerance as they maintain normal immune homeostasis [1, 2, 3] . Originally defined by high expression of CD25 (a subunit of the IL-2 receptor) [4] , nT REG cells are now primarily characterized by expression of the transcription factor Foxp3 [5, 6, 7, 8] . Stable expression of Foxp3 is essential for the development, homeostasis and suppressive function of nT REG cells [8, 9] . Functional abrogation of Foxp3 in mice (scurfy mice) and humans (IPEX syndrome) leads to the development of lethal multiorgan autoimmune and inflammatory diseases [10, 11, 12] . On the other hand, forced expression of Foxp3 in conventional CD4 + CD25 2 T cells is sufficient for the acquisition of suppressive activity in vitro and in vivo [5, 6, 7, 13] . Furthermore, the analysis of GFP knock-in, Foxp3 deficient mice revealed that the absence of Foxp3 protein abrogates nT REG suppressive activity, but is dispensable for the maintenance of nT REG cell anergic phenotype [14] .
The notion that Foxp3 + T REG cells represent a stable, terminally-differentiated lineage has been recently addressed.
The transient nature of Foxp3 expression in induced T REG (iT REG ) cells in vitro [15] combined with the potential of Foxp3 + nT REG cells to differentiate into Th17 cells in the presence of IL-6 and TGF-b [16, 17, 18] suggested that Foxp3-expressing T REG cell subsets manifest functional adaptation under certain conditions at least in vitro. Recent studies reported the down-regulation of Foxp3 expression in nT REG cells in vivo under lymphopenic conditions [19, 20, 21] or in organ-specific autoimmunity [22] . Although these reports highlight the functional plasticity of the Foxp3 + nT REG cell lineage, more recent studies argue against this phenomenon and propose that Foxp3 + T REG cells are refractory to this functional reprogramming [23, 24] . As T REG cell-based therapy is proposed as a treatment in autoimmune and transplantation settings, it is critical to assess the stability of Foxp3 + T REG cells and dynamics of there function or reprogramming under inflammatory conditions. Recent evidence clearly identifies the mammalian target of rapamycin (mTOR), a conserved serine-threonine protein kinase inhibited by the immunosuppressive drug rapamycin, as a master metabolic regulator that integrates environmental cues from nutrients, growth factors and stress conditions to drive cell growth, proliferation and T cell differentiation. More specifically, inhibi-tion of mTOR signalling, either through gene deficiency or rapamycin treatment, promotes T REG differentiation [25, 26, 27] while blunting Th17 differentiation and function in vitro and in vivo [28] . Currently, the role of mTOR signalling in the process of nT REG cell reprogramming is not well understood.
In this study, we show that the stability of Foxp3 + nT REG cell phenotype and function is a dynamic process modulated by inflammatory signals. Thymic or peripheral Foxp3
+ nT REG cells manifest prominent functional plasticity and readily reprogram into Th1 and Th17 effector cells, particularly in the gut microenvironment or sites of parasitic infection. nT REG cell reprogramming is a characteristic of the entire Foxp3
+ nT REG population and the stable, reprogrammed T REG cell phenotype is associated with a methylated foxp3 promoter. The extent of nT REG cell reprogramming is modulated by effector T (T EFF ) cellmediated signals but occurs independently of IL-2 dose variations in vivo. Reprogrammed Foxp3 + T REG cells predominantly produce IL-17, the expression of which precedes Foxp3 down-regulation, a process promoted in the intestinal microenviroment. Lastly, we report a mechanism whereby mTOR inhibition by rapamycin, stabilizes Foxp3 expression and prevents nT REG cell reprogramming into Th1/Th17 effectors in vivo. Thus, inflammatory signals may modulate mTOR function and impact the stability of the Foxp3 + T REG cell phenotype.
Materials and Methods

Mice
WT, TCRb 2/2 and Ly5.1 congenic C57BL/6 mice were obtained from Taconic Laboratories, GFP transgenic C57BL/6 (GFPtg) mice were provided by C. Schaefer [29] , Foxp3 GFPki mice were obtained from A. Rudensky (Memorial Sloan-Kettering Cancer Center) and Ly5.1 Foxp3
GFPki congenic line were generated in our laboratory. All mice were bred and maintained in a specific pathogen-free animal facility at McGill University.
T cell subsets purification and adoptive transfer
Various CD4
+ T cell subsets were separated from AutoMACSenriched CD4
+ T cells using a FACSAria TM Cell Sorter (BD) (purity .98%) or the autoMACS Cell Sorter (Miltenyi Biotec) (purity ranging 85-95%), as described previously [30] . For adoptive transfer studies, T cell subsets were transferred i.v. into TCRb 2/2 or RAG2 2/2 recipient mice. For adoptive transfer studies, T cell subsets were transferred i.v. into TCRb 2/2 or RAG2 2/2 recipient mice.
Lymphocyte isolation from lamina propria
To isolate lymphocytes from lamina propria (LP), a protocol from Weigmann et al. was used [31] .
Antibodies and flow cytometry
For surface phenotyping the following mAbs were used: anti-CD4 (RM4-5), anti-CD25 (PC61), anti-CD3 (145-2C11) and antiLy5.1 (A120) (eBioscience or BD Bioscience). The expression of Foxp3 (PJK-16s) (e-Bioscience) and Ki-67 (B56) (BD Bioscience) was determined by intracellular staining performed according to the manufactures protocol (e-Bioscience). To determine the cytokine production, lymphocytes were re-stimulated for 4 hrs at 37uC with PMA (20 ng/ml), ionomycin (1 nM) and BD GolgyStop TM (1:1000 dilution) and then stained intra-cellular with anti-IFN-c (XMG1.2), anti-IL-17 (TC11-18H10.1 or eBio17B7), anti-IL-10 (JES5-16E3), anti-IL-2 (JES6-5H4) (purchased from eBioscience or BD Bioscience) as described above. Data was acquired on FACSCanto (Becton Dickinson, Mountain View, CA) and analysed using FlowJo software (Tree Star).
In vivo therapy
In vivo IL-2 treatment was performed by i.p. injection of 5, 10 or 50 ng of recombinant human IL-2 (rhIL-2) (a kind gift from the Surgery Branch, NCI). In vivo rapamycin treatment (0.8 mg/kg) (Sigma) was performed by every other day i.p. injection starting one day post T cell-adoptive transfer.
In vitro T cell functional assay
For in vitro proliferation, 5610 4 FACS-sorted T cells were plated with 2610 5 irradiated total splenocytes and activated with soluble anti-CD3 (1 mg/ml) in the presence or absence of IL-2 (100 u/ml). For suppression assays, 5610 4 FACS-sorted CD4 + Foxp3 2 (GFP 2 ) responder T cells were plated alone or together with T cell subsets at various ratios and activated as described above. For the last 12 hrs of culture, 3 H-thymidine (0.5 mCi) was added and its incorporation was used to assess cell proliferation. To examine Foxp3 stability, CD4
+ T cell subsets were stimulated with platebound anti-CD3 (5 mg/ml) in the presence of IL-2 (100 m/ml).
Leishmania cultures and infections
Leishmania promastigotes were cultured as previously shown [32] . Mice were infected with 5610 6 stationary phase WT or GP63 2/2 (a gift from W.R. McMaster from UBC, Vancouver) [33] L. major into the right hind footpad. Disease progression was assessed and presented as a delta footpad swelling calculated by subtracting the measurement of infected footpads from noninfected footpads.
Sodium bisulfite mapping of DNA methylation
Epitect Bisulfite Kits (Qiagen) were used for bisulfite conversion of DNA as described in the manufacturer's manual. Briefly, samples were prepared by performing nested PCR with one of the nested primers carrying a 59 biotin modification. Primers (IDT Technologies) designed against bisulfite-converted DNA and targeting the TSDR locus were: outside -TTGAAGATTTAAGGGGGTTT-TAAT (forward), ACAAATAATCTACCCCACAAATT (reverse); nested -GGTTTTTTTGGTATTTAAGAA AGA (forward), biotinylated -CAAATAATCTACCCCACAAATTTC (reverse). PCR conditions consisted of initial denaturation/enzyme activation at 95uC for 3 min, 40 cycles of 95uC for 30 sec with a respective annealing temperature of 72uC for 30 seconds, and completed with a final extension step at 72uC for 4 minutes. Pyro Sequencing was then performed using a PyroMark Q24 machine according to the manufacturer's manual. Briefly, nested PCR products were incubated with sepharose beads (GE Healthcare) and agitated for 5 minutes, then washed in 70% ethanol, denatured in 0.2 M NaOH and mixed with an annealing solution containing the relevant sequencing primers: region 1 -TTGGTATTTAAGAAAGATAG and region 2 -TAT TATTTTATTTGGGTTTA. The samples were then processed by the Pyro Sequencer, and the resulting percentage methylation at the targeted CpG sites calculated with the accompanying software (PyroMarkH Q24 Software).
Statistical analysis
Analyses were performed with a Student's t test. Values of p,0.05 were considered significant. GFPki reporter mice were introduced into T cell-deficient TCRb 2/2 recipient mice. As early as 4 days post adoptive transfer, we observed a significant loss of Foxp3 expression in donor T cells (Fig. 1A) . The frequency of Foxp3-negative T REG cells (Foxp3 +R2 ) progressively increased from 20% on day 7 to 80% on day 21 (Fig. 1A) , and reached a plateau by 4 weeks. The level of Foxp3 expression in residual Foxp3
Results
Loss of
+ cells remained unchanged suggests that the loss of Foxp3 expression in Foxp3 +R2 cells is not gradual (Fig. 1A) . Peripheral induced T REG (iT REG ) cells have been shown to have a less stable phenotype in vitro [34, 35] , and may represent the major source of emerging Foxp3 +R2 T cells in the peripheral immune system [19] . We then assessed whether Foxp3
+ T REG cells from thymus, the primary developmental site for nT REG (Fig. 1D) . At a physiological 10:1 T EFF /T REG cell ratio, the frequency of Foxp3 +R2 cells decreased from 70% to 30%, reaching a maximal reduction at a 100:1 T EFF /T REG cell ratio (Fig. 1D) cells, during immune reconstitution does not stabilize Foxp3 expression in T REG cells (Fig. 1E) .
Collectively, our results show that highly purified T REG cells from peripheral lymphoid tissues, and particularly from thymic origin, readily down-regulate Foxp3 expression in the lymphopenic environment, a process modulated by the degree of T EFF cell occupancy in the periphery.
Foxp3
+R2 T REG cell phenotype is stable and correlates with a methylated Foxp3 promoter
We then sought to determine whether the Foxp3 +R2 T cell phenotype is stable in vitro and in vivo. To this end, we FACS purified Foxp3
+R2 and Foxp3 +R+ T cells from recipient mice, and then examined the level of Foxp3 expression after in vitro TCR re-stimulation under undifferentiated conditions ( Fig. 2A) . Neither of the fractions showed a significant change in their phenotype after 4 days of culture ( Fig. 2A) . Although Foxp3 +R2 T cells reacquired some Foxp3 (GFP) expression, this induction was nonetheless minor (1-3%) in this system.
In order to assess the stability of their phenotype in vivo, Foxp3
+R2 and Foxp3 +R+ T cells were isolated from the first recipients and re-transferred into secondary TCRb 2/2 recipients.
Freshly-isolated Foxp3
+ and Foxp3 2 T cells from Foxp3 GFPki mice were used as control cells. Upon secondary adoptive transfer, the majority of Foxp3
+R+ cells lose their Foxp3 expression (data not shown), similarly to freshly-isolated T REG cells, suggesting that the capacity to convert into conventional T cells is a universal feature of total Foxp3
+ T REG cells rather than the unique potential of a distinct Foxp3
+ T cell subset as was recently suggested [19] .
Interestingly, 15-20% of Foxp3
+R2 T cells re-expressed Foxp3 in different secondary lymphoid tissues examined, a percentage that is greater than the frequency of Foxp3 + cells (,5%) in recipients reconstituted with freshly-isolated T EFF cells (Fig. 2B ). These data indicate that the Foxp3
+R2 cell population has a stable phenotype in vivo, although a subset of these cells can regain Foxp3 expression.
The establishment of the stable Foxp3 + T REG cell lineage requires selective demethylation of CpG motifs in an evolutionarily conserved element within the foxp3 locus named TSDR (T REG -specific demethylated region) [15, 36] , and this epigenetic imprinting in the TSDR is completely lost in Foxp3 2 T EFF cells.
To establish whether Foxp3
+R2 T cell fraction demonstrate different epigenetic modifications compared to naive Foxp3 2 or Foxp3 +R+ T cells, we performed bisulphite sequencing of eight evolutionarily conserved CpG motifs within the TSDR of different T cell population isolated from recipient mice following adoptive T cell transfer (Fig. 2C) , as reported previously [36] . Importantly, our data shows that all eight CpG motifs of the TSDR are methylated in Foxp3 +R2 T cells (data not shown), in contrast to Foxp3 +R+ T cells isolated from the same recipient mice. The total TSDR methylation status (averaged from eight different sites) resembles that of freshly-isolated Foxp3 2 T EFF cells or in vivo activated Foxp3
2R2 T EFF cells (Fig. 2C ), confirming that Foxp3 promoter methylation underlies the stable phenotype of Foxp3 +R2 T REG cells in vivo.
Foxp3
+R2 T cells lose their T REG cell phenotype and reprogram into Th1 and Th17 effector cells in lymphopenic hosts
We then investigated whether the loss of Foxp3 led to a deficiency in T REG cell function. To this end, we tested their capacity to respond to TCR-induced proliferation and suppressive function in vitro. Foxp3 +R2 T cells proliferated in vitro with a slightly greater rate than freshly-isolated T EFF cells even in the absence of exogenous IL-2 ( Fig. 3A) . In contrast, Foxp3
+R+ cells retained their unresponsiveness to TCR-induced proliferation (anergy), and proliferated only in the presence of exogenous IL-2 (Fig. 3A) . More importantly, Foxp3
+R2 cells completely lost their suppressive function in vitro in contrast to Foxp3 +R+ cells, which efficiently suppressed proliferation of responding T EFF cells (Fig. 3B) 
CD4
+ T cells from lymphoid tissues of secondary recipient mice were (B) re-analyzed for Foxp3 expression or (C) sorted according to GFP expression and total genomic DNA was subjected to methylation analysis of Foxp3 promoter region. The percentage of lymphopenic hosts led to a significant lymphocytic infiltration in the colon in contrast to the Foxp3 +R+ cell transfer (data not shown). These results indicate that Foxp3 +R2 T cells lose the bona fide T REG phenotype, and gain the behaviour of conventional T EFF cells in vitro and in vivo.
To further examine whether Foxp3 +R2 cells can acquire functional properties of T EFF cells, LN cells from TCRb 2/2 recipient mice reconstituted with FACS-purified Foxp3 + T REG cells were re-stimulated ex vivo with PMA and ionomycin and analyzed for the production of pro-inflammatory cytokines relative to Foxp3 expression (Fig. 3C ). We show that over 30% of Foxp3 +R2 T cells produced high levels of IL-2, IFN-c and IL-17 and show a decreased production of IL-10 in contrast to Foxp3 +R+ cells which show low frequencies of IL-2 and IFN-c secreting T cells (,5% and 10% respectively). Although the frequency of IL-17-producing cells within stable Foxp3
+R+ T REG cell fraction was comparable to Foxp3 +R2 T cells (up to 30%), the magnitude of cytokine expression (i.e. MFI) was significantly lower in Foxp3
+R+ cells (Fig. 3C) . Thus, Foxp3 down-regulation in committed T REG cells impacts their cell fate and differentiation, and forces their reprogramming into Th1 and Th17 effector cells in lymphopenic hosts.
Intestinal inflammation or parasitic infection favours the reprogramming of Foxp3 + T REG cells into effector T cells and promotes host immunity
We then compared Foxp3 expression in donor T REG cells from different lymphoid tissues. We observed a 2-3 fold reduction in the conversion of Foxp3 + T REG cells into Foxp3 2 T cells in perLN compared to mesLN of recipient mice (20-30% vs 80%) (Fig. 4A) . Furthermore, the greatest Foxp3 down-regulation in donor T REG cells was observed in LP as the frequency of Foxp3 +R2 T cells in this site reached 90% (Fig. 4A) . These data suggest that the intestinal microenvironment is conducive for the conversion of Foxp3 + T REG cells into conventional Foxp3 2 T cells. A distinct characteristic of mucosal tissues is the constant stimulation of the local immune system with bacterial antigens. Notably, TCRb 2/2 mice are known to manifest spontaneous inflammation specifically in the intestine in the absence of any immune reconstitution. Moreover, this inflammatory response is known to be driven by the intestinal flora [37] . The analysis of inflammatory cytokines at the different sites upon T REG cell transfer shows a 2-and 8-fold increase of total IL-17 and IFN-c secretion, respectively, in mucosa associated tissues compared to perLN (Fig. 4B ). This suggests that the increased production of inflammatory cytokines in the gut correlates directly with an increased down-regulation of Foxp3 in donor T REG cell population in mesenteric sites.
To directly assess the role of local, microbial-induced inflammation in T REG cell reprogramming, we used a model of cutaneous L. major infection. To this end, we inoculated intradermally L. major promastigotes into the right hind footpad of TCRb 2/2 mice, and adoptively transferred GFPtg T REG cells 2 weeks post-infection. While control non-infected popliteal LN (popLN) show a similar frequency of Foxp3 +R2 T cells compared to perLN in infected mice (,20%), we observe a dramatic increase in Foxp3 2 T cells in infected draining LN as 65% of donor T REG cells down-regulated Foxp3 expression (Fig. 4C) . Interestingly, L. major infected sites show a comparable frequency of Foxp3 +R2 cells compared to mesLN (Fig. 4C) suggesting that microbialinduced inflammation drives T REG cell reprogramming. We then determined whether the level of microbial-induced inflammation in the local T REG environment influences the extent of T REG cell reprogramming. To achieve this, we compared Foxp3 expression in donor T REG cells in recipient mice infected either with a WT strain of L. major or a mutant strain lacking GP63 (GP63 2/2 ), a key virulence factor directly involved in parasite-host interactions, and promoting Th1 immune responses in the infected host. Thus, GP63
2/2 L. major are less infectious and trigger attenuated inflammatory responses in vivo.
Infection with GP63 2/2 L. major resulted in reduced footpad swelling compared to WT strain (Fig. 4D ) and resulted in minimal leukocyte infiltration and IFN-c production, which was comparable to non-infected recipients (Fig. 4E, F) . We observed that the frequency of Foxp3 +R2 GFP + T cells in draining popLN of GP63 2/2 L. major infected mice was 2-fold lower compared to WT L. major infected recipients (35% vs 70% respectively) and slightly higher compared to non-infected recipients (35% vs 20% respectively) (Fig. 4G) . In addition, we show that the increased magnitude of Foxp3 down-regulation correlates with a significantly higher proportion of IFN-c secreting T cells in L. major infected sites, in stark contrast to non-infected LN (Fig. 4F) demonstrating that attenuated inflammatory conditions result in significantly reduced Foxp3 loss in donor T REG cells. Overall, our results show a direct, magnitude-dependent role of microbialinduced inflammatory signals in the down-regulation of Foxp3 expression and reprogramming in donor T REG cells. + T REG cells is IL-2, a cytokine primarily produced by activated T EFF cells. Fluctuations in the bioavailability of IL-2 in inflammatory sites may perturb the T REG / T EFF balance in these sites and trigger autoimmunity [38] [39] [40] [41] . Duarte et al. [20] recently showed that prophylactic IL-2 infusion in vivo can prevent Foxp3 down-regulation in T REG cells suggesting that a temporal deficiency in IL-2, possibly as a consequence of the absence of T EFF cells, was the initial trigger for Foxp3 loss in T REG cells. However, in our system, the delivery of high (50 ng) or low (5 ng) doses of rhIL-2, previously shown to be favourable for the homeostasis of Foxp3 + T REG cells and protection from autoimmune diabetes [40] , failed to prevent the loss of Foxp3 expression in donor T REG cells in all tissues examined (Fig. 5A) . Moreover, the time or frequency of treatment initiation did not change the outcome (data not shown). Interestingly, both low and high IL-2 dose treatments resulted in a significant increase in CD25 expression (MFI) and frequency of CD25 + cells solely within the stable Foxp3 +R+ T cell fraction but not in Foxp3 +R2 cells (Fig. 5B ). This suggests that Foxp3 +R+ T cells may be particularly sensitive to IL-2 signals in vivo.
We then assessed how the production of IL-2 in vivo related with the onset and magnitude of Foxp3 loss in donor T REG cells. Our earlier results show that unlike stable Foxp3 +R+ T REG cells, around 30% of Foxp3 +R2 T cells in mesenteric LN (mesLN) secrete IL-2 ( Fig. 3C ) as soon as they are detected in the system (Fig. 5C) . Interestingly, we show a 2-fold increase in the frequency of IL-2
+
Foxp3
+R2 T cells in mesLN compared to perLN (Fig. 5D ) despite the more significant loss of Foxp3 in donor T REG cells in mucosadraining LN. Thus, the magnitude of Foxp3 loss in donor T REG cells inversely correlated with the frequency of IL-2 secreting Foxp3
+R2
CD4
+ T cells. Overall, these results indicate that Foxp3 downregulation in donor T REG cells is not triggered solely by a deficiency in T cell-derived IL-2 in secondary lymphoid tissues.
Predominant IL-17 secretion precedes Foxp3 downregulation in reprogramming Foxp3
+ T REG cells, a process accentuated in mesenteric sites
To assess whether cellular expansion contributed to Foxp3 down-regulation in T REG cells, the level of Foxp3 expression in donor CFSE-labelled CD4 +
CD25
+ T REG cells was determined 3, 4, 5 and 10 days post adoptive cell transfer (Fig. 6A ). Our analysis shows that Foxp3 +R2 T cells emerge already by 3 days post T cell transfer in the mesLN, and Foxp3 down-regulation occurs only in actively proliferating T cells (Fig. 6A) . Interestingly, we observed a delay in the emergence of Foxp3 +R2 T cells in perLN compared to mesLN, although the proportion of divided donor T cells in both lymphoid tissues was similar (51% vs 39% at day 3 and 80% vs 80% at day 4) (Fig. 6A) . This finding strongly suggests that Foxp3 down-regulation in donor T REG cells is only partly attributed to the homeostatic proliferation during lymphopenia.
A kinetic analysis of cytokine production by Foxp3 +R2 and Foxp3 +R+ T cells revealed prominent IL-17 secretion, which temporally preceded IFN-c production in both fractions of donor T REG cells (Fig. 6B-E) . The predominant IL-17 secretion was particularly marked in Foxp3 +R2 T cells in mesLN (Fig. 6C, E) . +R2 and Foxp3 +R+ T cells increased with time, reaching respectively 30% and 10% at day 10, the proportion of IL-17 + cells did not vary (Fig. 6C, E 2R2 T cells (Fig. 6F) .
Interestingly, Foxp3
+R2 T cells still produced a comparable amount of IFN-c compared to conventional Foxp3 2 T EFF cells (Fig. 6F) , suggesting that the re-programmed Foxp3 +R2 T cells display a more pro-inflammatory IL-17-dominant phenotype.
mTOR inhibition stabilizes Foxp3 expression in T REG cells and strongly inhibits IL-17 but not ROR-ct expression in vivo
Rapamycin is an immunosuppressive drug which inhibits the mTOR signalling pathway and selectively promotes Foxp3 + T REG lineage differentiation in vitro and in vivo, while inhibiting the differentiation of Foxp3 2 T EFF cells [25, 42] . In order to examine whether Foxp3 down-regulation in donor T REG cells is mTOR pathway dependant, TCRb 2/2 recipient mice were treated with rapamycin every other day after Foxp3 + T REG cell transfer, and donor T cells from mesLN and perLN were analyzed for Foxp3 expression 7 and 14 days later. Our data show that while rapamycin did not have any effect on the level of Foxp3 expression in donor T REG cells in perLN, it potently inhibited Foxp3 downregulation in mesLN 14 days post adoptive transfer, consequently rescuing the proportion of Foxp3 + donor T REG cells from 27% up to 55% (Fig. 7A) . We also observed a significant decrease in IL-17-producing donor T cells following in vivo rapamycin treatment, whereas the frequency of IFN-c secreting T cells remained unchanged (Fig. 7B) . Reprogrammed Foxp3 +R2 T cells in both perLN and mesLN showed the most marked decrease (4-fold) in the proportion of IL-17-secreting T cells (Fig. 7B) . These results are consistent with previous studies illustrating rapamycinmediated inhibition of Th17 cells [28] .
As RORct is a critical factor for Th17 cell development, we hypothesized that inhibition of the mTOR pathway would prevent IL-17 secretion by abrogating RORct expression. Surprisingly, rapamycin treatment did not alter RORct expression either in reprogrammed Foxp3
+R2 or in stable Foxp3 +R+ T cells (Fig. 7C ), suggesting that inhibition of the mTOR pathway selectively influences other factors involved Th17 cell differentiation. Thus, rapamycin-mediated inhibition of mTOR activity stabilizes the Foxp3 + T REG cell pool, particularly in inflammatory mesenteric sites, and strongly inhibits Th17 cell development in vivo.
Discussion
It is commonly viewed that Foxp3-expressing T cells represent a stable, terminally-differentiated lineage responsible for suppression of a wide variety of immune responses and maintenance of peripheral self-tolerance. Recently, studies proposed that Foxp3 + T REG cells, or an unstable subpopulation found within, retains developmental plasticity, whose modulating factors have yet to be clearly elucidated [19] [20] [21] .
Here [19] . Only around 20% of Foxp3 +R2 T cells regain Foxp3 expression suggesting that TCR re-activation in Foxp3 +R2 T cells does not re-establish the ''memory'' of original Foxp3 expression in parent cells by enabling de novo active transcription at the remodelled foxp3 locus [15] .
We show that while Foxp3 loss is primarily seen in actively dividing T REG cells in lymphopenic mice, the pre-existing T EFF / T REG ratio is an important variable in Foxp3 +R2 T cell generation. We observe that the increased frequency of total or effector CD4
+ T cells co-transferred with T REG cells reduces the magnitude of the loss of Foxp3 expression in T REG cells. The minimal loss of Foxp3 expression (15%), achieved at high 100:1 T EFF /T REG ratio, correlates with the basal level of the Foxp3 down-regulation detected in normal lymphoreplete mice [22] , suggesting that the degree of total reconstitution in lymphopenic hosts prevents Foxp3 loss. Moreover, co-transfer of similar numbers of T REG cells does not modulate the level of Foxp3 down-regulation, suggesting that the total degree of Foxp3 loss may correlate with a lack of occupancy of T EFF cell niches or T EFF derived signals.
The particular T EFF cell-mediated signals that stabilize Foxp3 expression are still unknown. IL-2, a likely candidate, was recently shown to prevent Foxp3 down-regulation in T REG cells suggesting that a temporal deficiency in IL-2, possibly as a consequence of the absence of T EFF cells in the periphery, was the initial trigger for Foxp3 loss in T REG cells [20] . Several lines of evidence from our study do not support a causative role for an IL-2 deficiency in the generation of Foxp3 +R2 T cells. We show that the magnitude of in T cell-derived IL-2 in secondary lymphoid tissues. Moreover, both low and high dose prophylactic IL-2 treatments resulted in a significant increase in CD25 expression and frequency of CD25 + cells only within the stable Foxp3 + T cell fraction suggesting that IL-2 preferentially favours the fitness of stable Foxp3
+R+ T REG cells without preventing T REG cell reprogramming.
The greatest degree of T REG cell plasticity was observed in the gut microenvironment, and reprogramming of T REG cells associated with significantly higher production of pro-inflammatory cytokines, particularly IL-17, in mesenteric sites. The more elevated basal inflammation induced by the constant exposure to commensal microbes coincides with the magnitude of Foxp3 +R2 cell reprogramming. This correlates with the recently published study indicating the gastrointestinal tract is a specific site for generation and control of Th17 cells [43] . Moreover, the locally induced infection with WT or attenuated form of L. major directly confirms that the magnitude of pathogen-induced inflammation is a critical factor in the emergence of T EFF cells from Foxp3 + T REG cell population. The possibility of concomitant recruitment of reprogrammed Foxp3 +R2 cells to inflammatory sites from other lymphoid sites cannot be excluded. While the nature of the innate signals remain unidentified, the substantial emergence of IL-17 producing cells in both Foxp3 2 and Foxp3 + fractions of donor T REG cells indicates the involvement of Th17 promoting factors in generation of Foxp3 +R2 T cells. In vitro, IL-6 inhibits Foxp3 expression in vitro [18] and, in combination with TGF-b, promotes the generation of IL-17 producing cells from conventional [44, 45] or regulatory T cells [16, 17] . Recently, it was shown that L. major infection triggers IL-6 secretion in DC [46] and keratinocytes [47] , and that IL-6 neutralization, together with an exacerbated L. major-induced pathology, increased local T REG cell numbers in the site of infection [48] . Thus, these data suggest a role for Th17 polarizing factors not only in anti-parasitic immunity but also in the reprogramming of T REG cells into Foxp3 2 T EFF cells. The PI3K/Akt pathway primarily signals through the mTOR, a master regulator that integrates metabolic, environmental and inflammatory cues, which ultimately promotes cell growth, proliferation, and T cell differentiation. More specifically, PI3K/ Akt/mTOR signalling abrogates T REG cell differentiation, and over-expression of an active form of Akt abrogates TGF-b-induced Foxp3 expression in CD4 + T cells [26, 49] . Our results demonstrate that mTOR inhibition by rapamycin, prevents Foxp3 down-regulation, stabilizes the Foxp3 + T REG cell pool, particularly in the inflammatory gut microenvironment, and strongly inhibits T REG cell reprogramming into Th1 and Th17 effectors in vivo. These results are consistent with previous studies showing that similar inhibition of mTOR signalling, either through genetic deletion or rapamycin treatment, promotes T REG differentiation while blunting T EFF cell differentiation and function in vitro and in vivo [25, 27] . Furthermore, we show that Foxp3 + T REG cells readily express significant levels of RORct, as confirmed by previous studies [50, 51] , and indicates that rapamycin-mediated inhibition of IL-17 production by reprogrammed Foxp3 +R2 T cells does not correlate with a reduction in RORct expression and may selectively influence other factors involved Th17 cell differentiation. Overall, our results suggest that changes in metabolic, inflammatory or environmental signals within the T REG cell microenvironment modulate mTOR function, and may impact the stability of the Foxp3 + expression and T REG cell function in settings of tolerance or immunity.
A lingering, controversial question concerns the cellular origin of newly-generated Foxp3 +R2 T cells. Recently, a study by Komatsu and colleagues [19] suggests that only a small fraction of Foxp3 + nT REG cells, negative for CD25 expression, possesses the ability to convert into Foxp3 2 T cells in contrast to the Foxp3 +
CD25
+ cell subset representing a stable T REG population. In our study we cannot attribute the down-regulation of Foxp3 to any particular subpopulation of nT REG + T REG population rather than a specific fraction exhibits this functional plasticity.
Overall, the findings of this study highlight the dynamics of Foxp3 expression in committed Foxp3
+ T REG cells, and point to the nature and magnitude of inflammation as critical factors modulating the plasticity of Foxp3 + T REG cells. As peripheral Foxp3 + T REG cells display an augmented potential for Foxp3 down-regulation compared to thymus-derived Foxp3
+ T cells, caution should be taken in designing future therapeutic studies involving T REG cell infusions. However, as no inflammation or disease induction was observed in T REG cell-reconstituted recipient mice even with a maximum degree of Foxp3 downregulation, this may suggest that the consequence of this T REG cell plasticity is to ensure the occupancy of the conventional T cell niche by Foxp3 +R2 T cells in the lymphopenic environment and maintain a T EFF /T REG equilibrium in the peripheral immune system.
